Hematology | Topics

 
Alina Markova, MD, on Key Findings With Topical Ruxolitinib in Cutaneous Chronic GVHD
May 10, 2022

Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Dearth of Participation From Black Patients Noted in CAR T Clinical Trials Supporting FDA Approvals
May 09, 2022

Investigators identified that in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with hematologic cancer, Black patients were significantly underrepresented.

The Role of Photopheresis for GVHD Following Progression
May 05, 2022

A panel of experts shares key insights into the role of photopheresis when patients with GVHD progress following initial treatment and emphasize its potential for patients with high skin involvement.

Clinical Scenario 2: Steroid-Refractory Chronic GVHD
May 05, 2022

Key opinion leaders in stem cell transplant and cellular immunotherapy review therapeutic considerations for the clinical scenario of a patient with steroid-refractory chronic GVHD.

Enrollment Low for Black Patients With Hematologic Malignancies On Trials Supporting FDA Approvals of CAR T-Cell Therapy
April 28, 2022

Investigators observed low enrollment of Black patients on CAR T-cell therapy clinical trials that supported FDA decisions in hematologic malignancies, especially in multiple myeloma.

The Effect of Trial Design on Approval of GVHD Therapies
April 28, 2022

Panelists consider the importance of studying trial drugs in a blinded, randomized fashion to mitigate physician and patient bias regarding patient-reported outcomes for GVHD therapies.

Clinical Scenario 1: First- and Second-Line Treatment for GVHD
April 28, 2022

John F. DiPersio, MD, PhD, presents the clinical scenario of a 71-year-old patient postmatched unrelated donor HSCT, and the panel discusses first- and second-line treatment approaches including topical and systemic therapies.

Study of Response to SARS-CoV-2 Vaccine Reveals Heterogeneous Outcomes in cGVHD
April 27, 2022

Patients with chronic graft-vs-host disease who were administered full series of the SARS-CoV-2 vaccine displayed varied immune responses, regardless of baseline characteristics.

Total Body Irradiation Plus Prophylactic PTCy, Tac, and MMF Yields Low cGVHD Incidence in Hematologic Cancer
April 27, 2022

Patients with hematologic cancer experienced a low incidence of chronic graft-versus-host disease after receiving a regimen consisting of myeloablative hematopoietic cell transplantation and total body irradiation plus prophylactic post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.

Itolizumab Prompts Release of Cell-Surface CD6 in aGVHD
April 26, 2022

In the phase 1b EQUATE trial, patients with acute graft-versus-host disease had decreased levels of cell-surface CD6 when treated with itolizumab.